[1].NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma. Version 1.2025 审批编号:CN-146864有效期至:2025-01-06 本材料由阿斯利康提供,仅供医疗卫生专业人士参考 更多医疗资讯,...
参考文献: [1] NCCN Guidelines Version 1.2023 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. [2] Tam CS, Brown JR, Kahl BS, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, ...
2.NCCN Clinical Practice Guidelines in Oncology for CLL/SLL. V3.2020. 3.https://www.clinicaloptions.com/oncology/programs/personalizedcll/clinician-resource/resource?origin=2 指南原文请见“阅读原文” 精彩回顾(点击查看) 儿童急性淋巴细胞白血病的化学治疗,看看...
[5]Hallek M, Cheson BD, Catovsky D,et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14. PMID: 29540348. [6]Wierda WG, Raws...
[8].NCCN Clinical Practice Guidelines in Oncology-Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(2023 Version 2)[DB/OL]. http://www.nccn.org. [9].NCCN Clinical Practice Guidelines in Oncology-Waldenström Macroglobulinemia / Lymphoplasmacytic Lymphoma(2023 Version 1)[DB/OL]. http://www...
1.Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood , 2008, ...
iwCLL guidelines for diag- nosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745-2760.Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of ...
[11] NCCN Guidelines. Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma. V2.2023. [12] NCCN Guidelines. B-Cell Lymphomas.V2.2023. [13] NCCN Guidelines. Waldenström Macroglobulinemia / Lymphoplasmacytic Lymphoma.V1.2023. [14] CSCO 淋巴瘤诊疗指南 2023. ...
2.Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–2760. 3.Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE. Abeloff’s Clinical Oncology. 6t...
Acalabrutinib (CALQUENCE®) is a NCCN Category 1 preferred treatment option for CLL in the NCCN Clinical Practice Guidelines for Oncology (NCCN Guidelines®)9 Acalabrutinib with or without obinutuzumab is recommended as a Category 1 preferred treatment option for patients with previously untreated...